2 Information about ofatumumab

Marketing authorisation indication

2.1 Ofatumumab (Kesimpta, Novartis) is indicated for the treatment of relapsing forms of multiple sclerosis in adults with active disease defined by clinical or imaging features.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics.


2.3 The list price for ofatumumab is £1,492.50 (excluding VAT) per unit pack (prefilled autoinjector pen). The company has a commercial arrangement. This makes ofatumumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)